Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 17 September 2026
      Blogs
 
  16 September 2026 World Patient Safety Day: Safer medicines start long before you take them (Guest blog)

Today, on World Patient Safety Day, we reaffirm that patients are at the center of everything we do. 

Read more →
 
 
 
  15 September 2026 Alzheimer's disease can't wait: the economic case for Europe to act now (Guest blog)

As we mark World Alzheimer's Month, attention is once again focused on the millions of people across Europe affected...

Read more →
 
 
 
      EU Screening Week

EU Screening Week mobilises partners across Europe to raise awareness of key cardiometabolic risk factors and to encourage people to speak to a health professional about checks such as blood pressure, cholesterol and blood sugar.

It is a European prevention moment linked to the Know Your Numbers campaign and the Safe Hearts Plan, presented by the European Commission in December 2025.

Through local activities, the EU Screening Week supports a simple message: get checked, know your numbers and take control of your heart health.

 

 
 
      Prioritizing and delivering prevention: Why Europe cannot afford to wait

From product development and regulatory pathways to access models and health service delivery, the way we assess and use medical innovation is geared towards therapeutics. New opportunities, arising from a deeper understanding of disease mechanisms and advances in diagnostics, allow for an enhanced public health model, with a shift from treatment to prevention. Unless we refocus and renew our systems, the full potential of preventive interventions will never be realized.

Key points:

  • Prevention is a powerful tool in public health with potential to improve lives and support health service sustainability;
  • Preventive health goes beyond lifestyle change to include immunization and medicines that reduce the risk of illness;
  • Established systems are designed for therapeutic interventions and may be suboptimal for prevention strategies;
  • New regulatory and access approaches are needed.

Learn more here.

 
 
 
      Events
 
 
23 SEP 2026
  How to navigate the parallel HTA and EMA processes in the EU Virtual

How can we work collaboratively for Europe? Mastering interface and breaking silos between regulatory and HTA.

Learn more →
 
 
 
30 SEP 2026
  Alzheimer’s in Europe: Turning innovation into patient access Brussels, Belgium

Alzheimer’s is at a turning point in Europe. As new treatments emerge, the real challenge is no longer just innovation,...

Learn more →
 
 
 
15 OCT 2026
  From EU ambition to national action: Strengthening Cardiovascular Health Plans across... Brussels, Belgium

Organised by the EFPIA Cardiovascular Health Platform and IPHA, this event will explore how the EU Safe Hearts Plan...

Learn more →
 
 
      What we are reading
Belgium needs cardiovascular plan by summer 2027, says cardiology head 15 September 2026  (Euractiv) Read more →
Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study 13 September 2026  (The Lancet) Read more →
Fixing Europe’s broken Life Sciences chain 11 September 2026  (Teresa Harris Graham) Read more →
EMA’s PRIME Scheme sets first-half record, eclipsing its weakest full year intake 27 July 2026  (Pink Sheet) Read more →
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
▶ in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe